ECSP15000868A - Derivados de estra–1,3,5(10),16–tetraeno 3–sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos - Google Patents

Derivados de estra–1,3,5(10),16–tetraeno 3–sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos

Info

Publication number
ECSP15000868A
ECSP15000868A ECIEPI2015868A ECPI201500868A ECSP15000868A EC SP15000868 A ECSP15000868 A EC SP15000868A EC IEPI2015868 A ECIEPI2015868 A EC IEPI2015868A EC PI201500868 A ECPI201500868 A EC PI201500868A EC SP15000868 A ECSP15000868 A EC SP15000868A
Authority
EC
Ecuador
Prior art keywords
preparation
methods
well
estra
tetraene
Prior art date
Application number
ECIEPI2015868A
Other languages
English (en)
Inventor
Tobias Marquardt
Matthias Busemann
Christian Stegmann
Naomi Barak
Andrea Rotgeri
Oliver Martin Fischer
Ulrich Bothe
Original Assignee
Poli Nutri Alimentos S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48748225&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP15000868(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Poli Nutri Alimentos S A filed Critical Poli Nutri Alimentos S A
Publication of ECSP15000868A publication Critical patent/ECSP15000868A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a inhibidores de AKR1C3 y a métodos para su preparación, su uso para el tratamiento y/o la prevención de enfermedades, así como a su uso para la preparación de medicamentos para el tratamiento y/o la prevención de enfermedades, en especial de trastornos hemorrágicos y endometriosis.
ECIEPI2015868A 2012-07-10 2015-01-09 Derivados de estra–1,3,5(10),16–tetraeno 3–sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos ECSP15000868A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102012211970 2012-07-10

Publications (1)

Publication Number Publication Date
ECSP15000868A true ECSP15000868A (es) 2016-01-29

Family

ID=48748225

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI2015868A ECSP15000868A (es) 2012-07-10 2015-01-09 Derivados de estra–1,3,5(10),16–tetraeno 3–sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos

Country Status (27)

Country Link
US (1) US9512169B2 (es)
EP (1) EP2872524B1 (es)
JP (1) JP6196302B2 (es)
KR (1) KR20150036319A (es)
CN (1) CN104428309B (es)
AP (1) AP2014008179A0 (es)
AR (1) AR092025A1 (es)
AU (1) AU2013289344A1 (es)
BR (1) BR112015000443A2 (es)
CA (1) CA2878485A1 (es)
CL (1) CL2015000039A1 (es)
CO (1) CO7160008A2 (es)
CR (1) CR20150007A (es)
DO (1) DOP2015000005A (es)
EA (1) EA201500112A1 (es)
EC (1) ECSP15000868A (es)
ES (1) ES2603258T3 (es)
IL (1) IL236581A0 (es)
MA (1) MA37742B1 (es)
MX (1) MX2015000347A (es)
PE (1) PE20150353A1 (es)
PH (1) PH12015500062A1 (es)
TN (1) TN2015000007A1 (es)
TW (1) TW201402596A (es)
UY (1) UY34899A (es)
WO (1) WO2014009274A1 (es)
ZA (1) ZA201500920B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2901632C (en) * 2013-02-21 2017-11-07 Bayer Pharma Aktiengesellschaft Estra-1,3,5(10),16-tetraene-3-carboxamides for inhibition of 17.beta.-hydroxysteroid dehydrogenase (akr1 c3)
ES2696848T3 (es) * 2014-09-11 2019-01-18 Bayer Pharma AG Inhibidores de oestra-1,3,5(10),16-tetraeno AKR1C3 sustituido con 3-nitrógeno o azufre
US10167293B2 (en) 2016-05-26 2019-01-01 Bayer Pharma Aktiengesellschaft [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanones
CZ307437B6 (cs) 2016-06-07 2018-08-22 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. 15β-substituované deriváty estronu jako selektivní inhibitory 17β-hydroxysteoiddehydrogenáz
EP3269373A1 (en) 2016-07-11 2018-01-17 Bayer Pharma Aktiengesellschaft Low-dosed oral dosage form of an akr1c3 inhibitor for treatment of diseases
CA3047191A1 (en) 2016-12-19 2018-06-28 Bayer Pharma Aktiengesellschaft [4-(phenylsulfonyl)piperazin-1-yl](1h-1,2,3-triazol-4-yl)methanones
TW201825478A (zh) 2016-12-19 2018-07-16 德商拜耳製藥公司 ［４－（苯基磺醯基）哌嗪－１－-基］（１ｈ－１，２，３－三唑－４-基）甲酮
EP3555101A2 (en) 2016-12-19 2019-10-23 Bayer Pharma Aktiengesellschaft [(phenylsulfonyl)octahydro-epiminoisoindol-yl](1h-1,2,3-triazol-5-yl)methanones
EP3421483A1 (en) 2017-06-29 2019-01-02 Bayer Pharma Aktiengesellschaft Novel steroidal 17-beta heteroaryl compounds as inhibitors of akr1c3
CN110693892A (zh) * 2018-07-09 2020-01-17 深圳艾欣达伟医药科技有限公司 化合物用于制备预防、治疗或改善疼痛的药物的用途
CN110272465A (zh) * 2019-07-15 2019-09-24 成都贝诺科成生物科技有限公司 阿比特龙衍生物、其制备方法与应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2265624B (en) * 1992-03-31 1995-04-19 British Tech Group 17-substituted steroids useful in cancer treatment
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
IL122740A (en) 1997-01-15 2003-09-17 Akzo Nobel Nv 16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them
BR9809748A (pt) 1997-04-07 2000-06-20 American Home Prod Estra-5(10), 7-dienos com atividade estrogênica
RU2000125533A (ru) 1998-03-11 2002-10-20 Эндорешерш, Инк. (Ca) Ингибиторы 17-бета-гидроксистероиддегидрогеназ 5 и 3 типа и способы их применения
CA2339368A1 (en) * 1998-08-07 2000-02-17 Endorecherche, Inc. Inhibitors of type 3 3.alpha.-hydroxysteroid dehydrogenase
EP1284272A4 (en) * 2000-04-24 2003-09-10 Kyowa Hakko Kogyo Kk ESTRA-1,3,5 (10) -TRIENE DERIVATIVES
EP1756139A4 (en) 2004-03-12 2009-07-29 Entremed Inc ANTI-ANGIOGENIC AGENTS
MX2008011127A (es) 2006-03-02 2008-10-31 Astellas Pharma Inc INHIBIDOR DE 17ß HSD TIPO 5.
CA2671075A1 (en) 2006-11-30 2008-06-05 Solvay Pharmaceuticals Gmbh Substituted estratrien derivatives as 17beta hsd inhibitors
MX2009006454A (es) 2006-12-22 2009-06-26 Hoffmann La Roche Derivados de espiro-piperidina.
CA2694216A1 (en) 2007-07-24 2009-01-29 Astellas Pharma Inc. Benzimidazole derivative
DE102011083725A1 (de) * 2011-09-29 2013-04-04 Bayer Pharma AG Estra-1,3,5(10),16-tetraen-3-carboxamid-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln

Also Published As

Publication number Publication date
AR092025A1 (es) 2015-03-18
AP2014008179A0 (en) 2014-12-31
CA2878485A1 (en) 2014-01-16
JP6196302B2 (ja) 2017-09-13
CO7160008A2 (es) 2015-01-15
EP2872524A1 (de) 2015-05-20
AU2013289344A1 (en) 2015-02-05
HK1205743A1 (en) 2015-12-24
US20150210734A1 (en) 2015-07-30
JP2015522050A (ja) 2015-08-03
KR20150036319A (ko) 2015-04-07
CR20150007A (es) 2015-03-13
MA37742B1 (fr) 2016-12-30
IL236581A0 (en) 2015-02-26
TN2015000007A1 (en) 2016-06-29
EP2872524B1 (de) 2016-08-24
CL2015000039A1 (es) 2015-03-27
DOP2015000005A (es) 2015-02-15
EA201500112A1 (ru) 2015-07-30
CN104428309B (zh) 2016-09-14
ES2603258T3 (es) 2017-02-24
PH12015500062A1 (en) 2015-03-02
UY34899A (es) 2014-02-28
MA37742A1 (fr) 2016-05-31
CN104428309A (zh) 2015-03-18
BR112015000443A2 (pt) 2017-06-27
TW201402596A (zh) 2014-01-16
MX2015000347A (es) 2015-04-14
PE20150353A1 (es) 2015-03-28
ZA201500920B (en) 2017-01-25
US9512169B2 (en) 2016-12-06
WO2014009274A1 (de) 2014-01-16

Similar Documents

Publication Publication Date Title
DOP2014000059A (es) Derivados de estra–1,3,5(10),16–tetraen–3–carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
DOP2015000005A (es) Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
CU20160087A7 (es) Indazolcarboxamidas, procedimientos para su preparación, preparaciones farmacéuticas que las contienen
MX389349B (es) Derivados de ácido borónico y usos terapéuticos de los mismos.
BR112017022604A2 (pt) composto, composição farmacêutica, uso de um composto e de uma combinação, e, combinação
UY35590A (es) Nuevos compuestos para el tratamiento del cáncer
BR112015011456A2 (pt) compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
CR20150326A (es) Inhibidores de autotaxina
MX2016008131A (es) Compuestos heterociclos biciclicos y sus usos en terapia.
IN2014DN06501A (es)
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
CU20140095A7 (es) Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CU20140081A7 (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
SV2018005760A (es) Derivados de aminotiazol utiles como agentes antiviricos
CO7310531A2 (es) 4-metil-2,3,8,9,9b-pentaaza-ciclopenta [a] naftalenos
BR112015020139A2 (pt) compostos terapêuticos e usos dos mesmos
DOP2015000170A (es) Compuestos químicos
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
EA201790949A1 (ru) Замещенные 2,4-диаминохинолины в качестве новых противораковых средств
BR112017009012A2 (pt) derivados de anel benzo de seis membros como inibidor de dpp-4 e seu uso
CR20170513A (es) Derivados de pirazol útiles como inhibidores de proteína activadora de 5-li-poxigenasa (flap).
UY33723A (es) ?COMPUESTOS Y SU USO PARA TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON Aß?.
BR112015015250A2 (pt) derivados de pirrolidina, composições farmacêuticas e usos dos mesmos